OZOlha Zaliska

Olha Zaliska

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Olha Zaliska has a total of 121 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Marketing research of medicinal products used for the treatment of primary cicatricial alopecia

    by N. P. Darzuli, N. M. Maksymovych, О. М. Zaliska

    Primary cicatricial alopecias belong to a group of chronic inflammatory diseases of the hair follicles that lead to their irreversible destruction and the formation of scar tissue. The complexity of diagnosis, limited therapeutic options, and the lack of unified approaches to treatment necessitate an assessment of the current range of medicinal products available for the pharmacotherapy of this pathology. The aim of the study was to investigate the structure and range of medicinal products on the domestic pharmaceutical market that are used for the treatment of primary cicatricial alopecias. The materials of the study were data on medicinal products registered on the pharmaceutical market of Ukraine as of 01.01.2026. Due to the absence of unified treatment protocols for primary cicatricial alopecias, the selection of medicinal products for marketing analysis was carried out on the basis of an analysis of current international scientific publications, clinical recommendations of professional dermatological associations, and data on the use of medicinal products in real clinical practice. It was established that 118 trade names (TNs) of medicinal products that can be used for the treatment of primary cicatricial alopecias are registered on the pharmaceutical market of Ukraine. By manufacturer origin, imported medicinal products predominate – 91 TNs (79%), whereas the share of domestic medicinal products is 27 TNs (21%). Capsules and tablets account for a significant share of the range – 35 TNs. Among medicinal products for topical use, ointments and creams predominate – 50 TNs, whereas systemic glucocorticosteroids are represented exclusively by injectable dosage forms. By composition, monocomponent medicinal products predominate – 89 TNs (75%), including all medicinal products of isotretinoin, tacrolimus, pimecrolimus, colchicine, hydroxychloroquine, and antibiotics. Combined medicinal products account for 29 TNs (25%) and are represented predominantly by betamethasone preparations for topical use. The results of the study indicate a significant dependence of the studied market segment on imported medicinal products and a limited range of agents for the treatment of primary cicatricial alopecias. The obtained data may be used to substantiate the prospects for expanding the range and developing domestic production of medicinal products for the treatment of primary cicatricial alopecias.

  • Open Access

    Analysis of legislative, informational, pharmacoeconomic aspects of pharmaceutical provision of pre-hospital care to military staff for 2014-2026 in Ukraine

    by O. M. Zaliska, A. I. Boiko, L. V. Hunko, Z. O. Zabolotnya, B. M. Zalisky, G. Yu. Yatskova

    In Ukraine, during the military operations in 2014‒2026, the basic first aid kit for the military is the Individual First Aid Kit (Ukraine IFAK), the requirements for which are changing. The aim was to systematize legislative acts on the nomenclature of the domestic Individual First Aid Kit for the military (Ukraine IFAK) to NATO standards for 2014‒2026 and retrospective analysis with the nomenclature of the first aid kit used in Afghanistan in 1979‒1989. To substantiate the directions of information support for continuous professional development of pharmacy professionals, which include the pharmacoeconomic analysis results for the rational use of budget and development of domestic production for the needs of the military. The study used the next methods: systemic, historical, content analysis of documents for 1978‒2026; retrospective, generalization, comparative, chronological analysis; pharmacoeconomic analysis «cost minimization». It was established based on the results of the analysis of the regulatory acts of the Ministry of Health and the Ministry of Defense of Ukraine for 1978–2026 that the formation of the composition and nomenclature of the Ukraine IFAK first-aid kit has significantly changed in accordance with the requirements of combat operations and NATO standards. It was established that for 2014–2026 there were 6 documents on the nomenclature of drugs and medical equipment, key changes in drugs and medical equipment were identified, practically harmonized with the nomenclature of the NATO US IFAK. It was found that paracetamol is included in the NATO first-aid kit in a dose of 650 mg of prolonged action for longer-term pain relief, but such a dosage form is absent on the Ukrainian market. Therefore, domestic pharmaceutical development of a paracetamol preparation in a dose of 650 mg of prolonged action for the Ukraine IFAK first-aid kit is promising. The results of the pharmacoeconomic analysis «cost minimization» for tourniquets showed that during the fourth year of the war 8 tourniquets were available in the Ukrainian market, but only 25% are domestic, it was established that Ukrainian tourniquets are 1.9–3.5 times more economically profitable than imported ones. Therefore it is advisable to expand domestic production.

  • Open Access

    Study of affordability of pharmaceutical provision for type 2 diabetes therapy in Ukraine

    by I.O. Vlasenko, V.V. Gladyshev, O.M. Zaliska, L.L. Davtian

    Increasing the availability and affordability of medical and pharma­ceutical care to the population is the most important task of all levels of government. The purpose of the work is to study the affordability of glucose-lowering drugs for the treatment of type 2 diabetes in Ukraine. Research materials are: State Register of Medicinal Products and price of glucose-lowering drugs. Marketing, analytical, graphic and pharma­coeconomic analysis were used. On the pharmaceutical market of Ukraine 161 glucose-lowering drugs are registered, which contain 16 international non-proprietary names and 8 international non-proprietary names combinations. It was established that the cost of Defined Daily Dose for mono glucose-lowering drugs varies from UAH 1,1 for glibenclamide up to UAH 90,7 for liraglutide. Most of the Ukrainian-made and foreign drugs are highly affordable, but foreign pre­parations of modern groups are moderately affordable, only one foreign drug, Liraglutide, is unaffordable ratio. But the analysis of affovailability for pensioners only metformin (Ukrainian production), glibenclamide, gliclazide, and glimepiride are highly affordable, three of which are already subject to reimbursement. Modern glucose-lowering drugs, both of foreign and Ukrainian production, is scarcely affordable, which makes it practically impossible to use them in the majority of retirees with diabetes. Thus, the analysis showed that in order to implement modern treatment schemes for type 2 diabetes, which according to the current legislation can be used in Ukraine, it is necessary to expand the list of glucose-lowering drugs included in the reimbursement program. This will improve treatment results, which in turn will reduce the development of diabetes complications and improve the quality of life of patients.


  • Open Access

    Overcoming Barriers in Hospital-Based Health Technology Assessment (HB-HTA): International Expert Panel Consensus

    by Iga Lipska, Rossella Di Bidino, Maciej Niewada, Bertalan Nemeth, Tomasz Bochenek, Monika Kukla, Barbara Więckowska, Alicja Sobczak, Katarzyna Iłowiecka, Antal Zemplenyi, et al.

    The purpose of this article is to investigate the common facilitators and barriers associated with the implementation of hospital-based health technology assessment (HB-HTA) across diverse hospital settings in seven countries. Through a two-round Delphi study, insights were gathered from a panel of 15 HTA specialists from France, Hungary, Italy, Kazakhstan, Poland, Switzerland, and Ukraine. Experts initially conducted a comprehensive review of the HB-HTA implementation in their respective countries, identifying the barriers and facilitators through descriptive analysis. Subsequently, panel experts ranked these identified barriers and facilitators on a seven-point Likert scale. A median agreement score ≥ 6 and interquartile range (IQR) ≤ 1 was accepted as reaching a consensus. Out of the 12 statements categorized as external and internal barriers and facilitators, the expert panel reached consensus on six statements (two barriers and four facilitators). The external barrier, which achieved consensus, was the lack of the formal recognition of the role of HB-HTA in national or regional legislations. The internal barrier reaching consensus was the limited availability of human resources dedicated to HB-HTA. This qualitative study indicates that HB-HTA still has progress to make before being formally accepted and integrated across most countries, although by building on the facilitating factors we identified there may be an opportunity for the implementation of internationally developed strategies to strengthen HB-HTA practices.


  • Open Access

    The study of the state of awareness of pharmaceutical workers regarding coronavirus disease (COVID-19)

    by O. M. Zaliska, О. М. Semenov

    Aim. To analyze and summarize the results of a questionnaire on the state of awareness of pharmaceutical workers in the Western regions of Ukraine about the coronavirus disease (COVID-19). Materials and methods. The results of a survey of pharmacy managers, pharmacists and interns working in pharmacies in 8 regions of the Western area of Ukraine were used. The survey of respondents lasted 12 months: December 2021 – December 2022. A special questionnaire was developed to determine the level of knowledge about the coronavirus disease (COVID-19) caused by the SARS-CoV-2 coronavirus. Results and discussion. With the beginning of the full-scale invasion of the Russian Federation, COVID-19 practically disappeared from the information space and ceased to be an urgent issue for Ukrainians. However, in recent weeks, the Ministry of Health has recorded an increase in the number of hospitalizations due to the coronavirus disease. During the period of martial law and the coronavirus disease pandemic (COVID-19), the pharmacy is the most accessible healthcare institution for the population and ranks first in terms of the number of citizens’ requests for symptoms, methods of treatment and prevention of SARS-CoV-2, therefore, the awareness of pharmacists – practitioners about COVID-19 is very important to provide complete and high-quality pharmaceutical care to patients. A review of the specialized scientific literature over the past 5 years confirmed the lack of studies on the level of awareness of pharmaceutical workers about the symptoms, methods of diagnosis, treatment and prevention of the main diseases that are widespread in the Western regions of Ukraine. With the help of a questionnaire, we conducted an expert assessment of the level of knowledge of pharmacy managers, pharmacists and interns working in pharmacy institutions in 8 regions of the Western area of Ukraine regarding the main symptoms, methods of diagnosis, treatment and prevention of uncomplicated forms of the coronavirus disease (COVID-19). After analyzing the answers of the respondents, it can be assumed that pharmaceutical workers know the main manifestations of the coronavirus disease (COVID-19) and are oriented towards the threatening indicators of the patient’s condition. It causes concern that some respondents incorrectly determine the reasons for prescribing antibacterial therapy to a patient, which can lead to incorrect recommendations and advice during the implementation of pharmaceutical care, however, the introduction of electronic prescriptions for dispensing antimicrobial drugs and information and educational work with pharmaceutical workers should correct the situation. Conclusions. In our opinion, it is promising to conduct further research to improve the level of knowledge and competencies of pharmaceutical workers during their specialization courses and thematic improvement in the system of continuous professional development


  • Open Access

    ВИВЧЕННЯ ФАРМАЦЕВТИЧНОГО ЗАБЕЗПЕЧЕННЯ ТЕРАПІЇ ЦУКРОВОГО ДІАБЕТУ 2 ТИПУ В УКРАЇНІ

    by I. O. Vlasenko, L. L. Davtian, O. M. Zaliska

    Мета роботи. Аналіз законодавства та рекомендацій щодо фармацевтичного забезпечення хворих на цукровий діабет 2 типу в Україні та вивчення доступності (наявності) цукрознижувальних препаратів для лікування цього захворювання згідно з рекомендаціями. Матеріали і методи. Об’єкти дослідження: рекомендації та нормативні документи щодо терапії цукрового діабету 2 типу, Державний реєстр лікарських засобів. Застосовували бібліосемантичний, маркетинговий, аналітичний, графічний, узагальнювальний аналізи. Результати й обговорення. Чинне законодавство України дає змогу використовувати лікарям сучасні міжнародні клінічні настанови для лікування ЦД, одночасно продовжує діяти Уніфікований клінічний протокол лікування цукрового діабету 2 типу (2012 р.). На фармацевтичному ринку України зареєстровано 161 цукрознижувальних препарат, які містять 16 міжнародних непатентованих найменувань, що складає 29,6 % від існуючого асортименту міжнародного ринку моно-цукрознижувальних препаратів. Із 27 існуючих комбінацій міжнародних непатентованих найменувань на світовому ринку в Україні зареєстровано 8 їх комбінацій. Більшу частину (64,0 %) асортименту зареєстрованих в Україні цукрознижувальних препаратів постачають іноземні виробники. Частина зареєстрованого асортименту цукрознижувальних препаратів в аптеках відсутня. Висновок. Порівняльний аналіз настанов показав, що український Уніфікований клінічний протокол потребує оновлення. Дослідження показало, що в Україні зареєстровано достатньо цукрознижувальних препаратів, що дає змогу використовувати сучасні схеми лікування цукрового діабету згідно з міжнародними рекомендаціями.


  • Open Access

    Research on the State of Awareness of Pharmaceutical Workers About Coronavirus Disease (COVID-19)

    by Oleksandr Semenov, Olha Zaliska, Ольга Заліська

    The article presents the results of a survey of 269 pharmaceutical workers to determine the level of knowledge of the etiology, pathogenesis, treatment and prevention of coronavirus disease (COVID-19) in order to provide complete and quality pharmaceutical care to patients. The objective: analysis and generalization of the results of the survey on the state of awareness of pharmaceutical workers in the western region of Ukraine about coronavirus disease (COVID-19). Materials and methods. The survey was conducted in Lviv among pharmacists-students of internship, specialization, thematic improvement and pharmacists-interns at the Department of Organization and Economics of Pharmacy, Drug Technology and Pharmacoeconomics Department of Management and Economy, Drug Technology and Pharmacoeconomics of Postgraduate Faculty Danylo Halytsky National Medical University. The first part of the questions concerned general information about the respondents. In the second part, respondents were asked questions about the main manifestations, threatening symptoms, surveillance measures, methods of treatment and prevention of uncomplicated coronavirus disease (COVID-19). Results. The results showed that pharmacists have theoretical knowledge about the pathogen, its routes of transmission, methods of diagnosis, treatment and prevention of uncomplicated forms of coronavirus disease (COVID-19), are guided by the threatening indicators of the patient, correctly determine the grounds for prescribing antibacterial drugs. Conclusions. Knowledge of the etiology, pathogenesis, treatment and prevention of the most common diseases and coronavirus disease (COVID-19) in particular plays an important role in the list of necessary competencies for the quality of professional development of a pharmaceutical worker.

  • Open Access

    АНАЛІЗ ТЕНДЕНЦІЙ У ПРОГРАМІ РЕІМБУРСАЦІЇ «ДОСТУПНІ ЛІКИ» В УКРАЇНІ

    by V. S. Huz, O. M. Zaliska, N. M. Maksymovych

    Мета роботи. Провести аналіз упровадження урядової програми реімбурсації «Доступні ліки» для амбулаторного лікування основними лікарськими засобами пацієнтів із серцево-судинними захворюваннями, цукровим діабетом 2 типу та бронхіальною астмою за 2019–2020 роки. Матеріали  і  методи. Об’єктами дослідження були дані з НСЗУ за 2019–2020 роки, а також Постанови КМУ, Накази МОЗ України про затвердження Реєстру лікарських засобів, вартість яких підлягає відшкодуванню у програмі «Доступні ліки». У дослідженні було використано методи частотного, порівняльного, логічного та контент-аналізу. Результати  й  обговорення. Розроблено методику аналізу програми реімбурсації з урахуванням районування території України за 5 макрорегіонами та проведено аналіз таких показників, як: бюджетне фінансування програми; кількість виписаних та відпущених електронних рецептів з 01 квітня 2019 року; розподіл електронних рецептів у програмі за віком та статтю пацієнтів; структура аптек за формою власності та типом населеного пункту. Виявлено, що обсяг бюджетного фінансування програми «Доступні ліки» у 2020 році зріс у 3 рази порівняно з 2017 роком. Кількість аптек у 2020 році зросла в 1,84 раза порівняно зі стартом програми. Більшість залучених до програми аптек розташована в містах Західного та Центрального макрорегіону. Встановлено, що у 2020 році найвищі темпи приросту, за досліджуваними параметрами, зафіксовані у Південному та Західному макрорегіонах країни. Впродовж 2019–2020 років понад 50 % е-рецептів було виписано на такі міжнародні непатентовані назви (МНН): бісопролол, клопідогрель, еналаприл та амлодипін. Висновки. Проведений аналіз програми реімбурсації виявив збільшення кількості аптек у 1,84 раза порівняно зі стартом програми у 2017 році. Згідно з регіональним розподілом та аналізом показників, найвищі показники приросту встановлені у Південному макрорегіоні. За досліджуваний період більше 50 % з усіх е-рецептів для лікування АГ було виписано для таких лікарських засобів як: бісопролол, клопідогрель, еналаприл та амлодипін.


  • Open Access

    Analysis of extemporal production trends in pharmacies for children

    by О. М. Заліська, Ю. В. Качерай, З. О. Заболотня, О. М. Семенов

    Medicines for children are insufficiently represented in pediatric dosages and appropriate dosage forms in the pharmaceutical market of Ukraine. Pediatricians are forced to prescribe children's medicines in dosages that are not available in the State Register of Medicines of Ukraine. Extemporaneously compounded medicines (ECM) are useful when a required dose or dose form is unavailable commercially, or is needed for individualised dosing. The aim of the study was to analysis a real data of the list of medicines which are produced in hospital and public pharmacies of Lviv region during 2020–2021. Methods. Content analysis of extemporal prescriptions for children, depending on the composition of the active pharmaceutical ingredient, dose and dosage form, comparative cost analysis of ECM and industrial medicines. In the hospital doctors prescribe ECМ in liquid forms (75%) – solutions for injection and in solid forms (25%) – dosed simple powders – 19%, dosed complex powders – 6%. It was determined the structure of ECM, which are produced in 6 studied pharmacies in 2020–2021. There are soft ECM 61.6% in dosage forms: ointments, creams, paste; liquid ECM are 28.3% in mixtures, solutions, mumbles; solid ECM are 8.3% in mono, combine powders, suppositories and 1.8% – other ECM: powders and nail polishs. There were highlighted unique recipes of ECM which analogues were not present in industrial dosage forms. We conducted analysis of the cost of children’s ECM in these pharmacies. It was determined that ECM cost were 40.5–305.6 UAH depending on the dosage form. The comparative analysis showed that ECM are in 2.2–4.9 times more cheaper for children compare with similar active ingredients in industrial medicines. ECMs are much more compliant for treatment in children and babies, they provide higher effect, safety, reduce dosing errors, especially at the inpatient stage, and continuation of therapy on an outpatient basis and more cost-effective for individual needs. The use of ECMs allows parents to properly dose them for children, to avoid errors in dosing, improper administration, which is extremely important to ensure the rational use of medicines in pediatric practice.